Commonly discussed for
Sleep, lean mass, fat loss, recovery, performance and anti-aging.
Traducción automática para su comodidad. Para decisiones médicas,
confirme los detalles con nuestro equipo bilingüe.
Not FDA-approved
CJC-1295: evidence, status & safety
CJC-1295 is a long-acting growth-hormone-releasing hormone analog studied for its effects on GH and IGF-1. It is not an FDA-approved drug.
What patients should know first
What efficacy data show
Small, short trials in healthy adults showed prolonged increases in GH and IGF-1. They did not establish durable improvements in body composition, injury recovery, function, healthspan or survival.
Approval boundary
A biomarker response is evidence of pharmacologic activity—not proof of a meaningful clinical benefit.
Safety context
FDA notes limited clinical data, immunogenicity and peptide-characterization concerns, and serious adverse events including increased heart rate and systemic vasodilatory reaction.
Why the distinction matters: showing that CJC-1295 can alter GH or IGF-1 establishes pharmacologic activity. It does not by itself demonstrate improved recovery, body composition, performance, longevity or another meaningful patient outcome.
Interpretation
Do not confuse a molecule with a verified medication
The name of an active ingredient does not verify the product in a vial. FDA approval, when it exists, applies to a specific product and indication. A compounded version is not FDA-approved, and a research-labeled product is not approved for human use.
Clinical supervision should include diagnosis, contraindication and interaction review, realistic outcome discussion, a valid prescription, traceable sourcing and follow-up. It cannot make an anonymous or counterfeit product safe.